Human chromaffin cell graft into the CSF for cancer pain management: a prospective phase II clinical study

Pain ◽  
2000 ◽  
Vol 87 (1) ◽  
pp. 19-32 ◽  
Author(s):  
Yves Lazorthes ◽  
Jacqueline Sagen ◽  
Brigitte Sallerin ◽  
Jean Tkaczuk ◽  
Hélène Duplan ◽  
...  
Keyword(s):  
Clinical Study ◽  
Pain Management ◽  
Cancer Pain ◽  
Phase Ii ◽  
Chromaffin Cell ◽  
Cancer Pain Management ◽  
Phase Ii Clinical Study ◽  
Prospective Phase

scholarly journals A Prospective Phase II Study Evaluating Intraoperative Electrochemotherapy of Hepatocellular Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3778
Author(s):  
Mihajlo Djokic ◽  
Maja Cemazar ◽  
Masa Bosnjak ◽  
Rok Dezman ◽  
David Badovinac ◽  
...  
Keyword(s):  
Clinical Study ◽  
Phase Ii ◽  
Treatment Options ◽  
Progression Free Survival ◽  
Complete Response ◽  
Local Tumor Control ◽  
Tumor Control ◽  
Durable Response ◽  
Phase Ii Clinical Study ◽  
Prospective Phase

The aim of this clinical study was to investigate the effectiveness and long-term safety of electrochemotherapy as an emerging treatment for HCC in patients not suitable for other treatment options. A prospective phase II clinical study was conducted in patients with primary HCC who were not suitable for other treatment options according to the Barcelona Clinic Liver Cancer classification. A total of 24 patients with 32 tumors were treated by electrochemotherapy. The procedure was effective, feasible, and safe with some procedure-related side effects. The responses of the 32 treated nodules were: 84.4% complete response (CR), 12.5% partial response (PR), and 3.1% stable disease (SD). The treatment was equally effective for nodules located centrally and peripherally. Electrochemotherapy provided a durable response with local tumor control over 50 months of observation in 78.0% of nodules. The patient responses were: 79.2% CR and 16.6% PR. The median progression-free survival was 12 months (range 2.7–50), and the overall survival over 5 years of observation was 72.0%. This prospective phase II clinical study showed that electrochemotherapy was an effective, feasible, and safe option for treating HCC in patients not suitable for other treatment options.

Chromaffin Cell Allograft for Cancer Pain Management

Neurosurgery ◽  
1999 ◽  
Vol 45 (3) ◽  
pp. 736-736
Author(s):  
Yves Lazorthes ◽  
Jean-Claude Bes ◽  
Brigitte Sallerin ◽  
Jean Tkaczuk ◽  
Mathieu Tafani ◽  
...  
Keyword(s):  
Pain Management ◽  
Cancer Pain ◽  
Chromaffin Cell ◽  
Cancer Pain Management

scholarly journals Ultra-Low-Dose Bevacizumab For Cerebral Radiation Necrosis: A Prospective Phase II Clinical Study

2019 ◽  
Vol Volume 12 ◽  
pp. 8447-8453
Author(s):  
Hongqing Zhuang ◽  
Hongxia Zhuang ◽  
Siyu Shi ◽  
Yuxia Wang
Keyword(s):  
Clinical Study ◽  
Phase Ii ◽  
Low Dose ◽  
Radiation Necrosis ◽  
Cerebral Radiation Necrosis ◽  
Phase Ii Clinical Study ◽  
Prospective Phase

Cancer pain management

2014 ◽  
Vol 155 (3) ◽  
pp. 93-99
Author(s):  
Péter Heigl
Keyword(s):  
Quality Of Life ◽  
Pain Management ◽  
Pain Relief ◽  
Life Expectancy ◽  
Cancer Pain ◽  
Cancer Pain Management ◽  
Medical Activity ◽  
Short Summary ◽  
Adequate Quality

Pain is a significant and alarming symptom of cancer seriously affecting the activity and quality of life of patients. Recent research proved that inadequate analgesia shortens life expectancy. Therefore, pain relief is not only a possibility but a professional, ethical and moral commitment to relieve patients from suffering, as well as ensure their adequate quality of life and human dignity. Proper pain relief can be achieved with medical therapy in most of the cases and the pharmacological alternatives are available in Hungary. Yet medical activity regarding pain relief is far from the desired. This paper gives a short summary of the guidelines on medical pain management focusing particularly on the use of opioids. Orv. Hetil., 2014, 155(3), 93–99.

Sign in / Sign up

Export Citation Format

Share Document